Experienced in Familial Multiple Nevi Flammei

John C. Su

Melbourne, VIC, AU 
Experienced in Familial Multiple Nevi Flammei
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

John Su practices in Melbourne, Australia. Mr. Su is rated as an Experienced expert by MediFind in the treatment of Familial Multiple Nevi Flammei. His top areas of expertise are Atopic Dermatitis, Parkes Weber Syndrome, Dominant Dystrophic Epidermolysis Bullosa, and Dowling-Meara Epidermolysis Bullosa Simplex.

His clinical research consists of co-authoring 70 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Familial Multiple Nevi Flammei.

Gender
Male

Locations

Melbourne, VIC, Australia
Other Locations
Box Hill, VIC, Australia
Parkville, NSW, Australia
Parkville, VIC, Australia
VIC, Australia
Box Hill, Vic, Monash, SA, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Baricitinib, Topical Corticosteroid
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
View 2 Less Clinical Trials

70 Total Publications

Psychosocial Determinants and Atopic Dermatitis Outcomes: A Cross-Sectional Study From an Australian Paediatric Centre.
Psychosocial Determinants and Atopic Dermatitis Outcomes: A Cross-Sectional Study From an Australian Paediatric Centre.
Journal: The Australasian journal of dermatology
Published: April 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Su's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile